675.3000 -2.65 (-0.39%)
NSE Mar 16, 2026 15:31 PM
Volume: 52,315
 

Deven Choksey
We maintain a positive FY26E outlook, expecting sustained double-digit growth across US, Ex-US, and RoW businesses. Growth across regions will be majorly driven by a healthy US pipeline, strategic expansion in RoW, and improved execution across India.
Alembic Pharma has lost -30.39% in the last 6 Months
More from Alembic Pharmaceuticals Ltd.
Recommended